LMN-201, an oral biologic drug developed by Lumen Bioscience, has received Fast Track Designation from the FDA. The drug combines therapeutic proteins to neutralize the bacterium and toxin that cause C difficile infection.
Today,
The orally administered biologic drug combines 4 therapeutic proteins that work together to neutralize both C diff and the toxin that causes its virulence in the gastrointestinal tract. LMN-201 is intended to be administered alongside standard-of-care antibiotics and for 8 weeks after to protect against reinfection while commensal bacteria recolonize the gut microbiome.
The purpose of the FDA’s Fast Track process is to expedite the development and review of drugs needed to fulfill unmet medical needs. “Fast Track Designation underscores the significant unmet need for treating and preventing C difficile infection and the potential of LMN-201 to address this persistent gap in patient care,” said Brian Finrow, cofounder and CEO of Lumen Bioscience.
The FDA had previously approved a phase 2/3 study of LNM-201, and Lumen intends to enroll approximately 375 patients across the United States later this year. The study’s primary objective is to prevent CDI recurrence, though a secondary endpoint will assess LMN-201’s ability to enhance primary treatment outcomes. The study, conducted in a double-blind, placebo-controlled manner, will assess LMN-201's efficacy in improving treatment outcomes and preventing recurrence in recently diagnosed CDI patients, without requiring prior CDI recurrence for enrollment.
LMN-201 is a complex biologic cocktail drug, and is taken in a capsule form that contains 2 classes of therapeutic proteins. The first class comprises 3 antibody-like proteins that bind and neutralize the bacterial toxin largely responsible for diarrhea and other severe CDI symptoms. The second class consists of an enzyme protein that targets and destroys the C diff bacterium's cell wall.
C diff is the most common healthcare-associated infection in American hospitals, causing significant morbidity and incurring substantial healthcare costs annually. While antibiotic therapy is initially successful, a substantial number of patients experience CDI recurrence. Current prevention approaches suffer from high costs and inconvenient administration. LMN-201 aims to address these challenges by providing an oral, shelf-stable solution that can be readily distributed to a wider patient population compared to other interventions available for CDI.
“Recent advances in CDI recurrence prevention are inspiring but have yet to make a perceivable impact on the epidemic, due in significant part to inconvenient administration requirements,” Finrow said. “We are committed to advancing our clinical program and bringing this innovative therapy to patients as quickly as possible, to provide relief to those suffering from this life-threatening disease.”
